Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2012

01.03.2012 | Original Article

18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials

verfasst von: Thida Win, Tryphon Lambrou, Brian F. Hutton, Irfan Kayani, Nicholas J. Screaton, Joanna C. Porter, Toby M. Maher, Raymondo Endozo, Robert I. Shortman, Pauline Lukey, Ashley M. Groves

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Noninvasive markers of disease activity in patients with idiopathic pulmonary fibrosis (IPF) are lacking. We performed this study to investigate the reproducibility of pulmonary 18F-FDG PET/CT in patients with IPF.

Methods

The study group comprised 13 patients (11 men, 2 women; mean age 71.1 ± 9.9 years) with IPF recruited for two thoracic 18F-FDG PET/CT studies performed within 2 weeks of each other. All patients were diagnosed with IPF in consensus at multidisciplinary meetings as a result of typical clinical, high-resolution CT and pulmonary function test features. Three methods for evaluating pulmonary 18F-FDG uptake were used. The maximal 18F-FDG pulmonary uptake (SUVmax) in the lungs was determined using manual region-of-interest placement. An 18F-FDG uptake intensity histogram was automatically constructed from segmented lungs to evaluate the distribution of SUVs. Finally, mean SUV was determined for volumes-of-interest in pulmonary regions with interstitial lung changes identified on CT scans. Processing included correction for tissue fraction effects. Bland-Altman analysis was performed and interclass correlation coefficients (ICC) were determined to assess the reproducibility between the first and second PET scans, as well as the level of intraobserver and interobserver agreement.

Results

The mean time between the two scans was 6.3 ± 4.3 days. The interscan ICCs for pulmonary SUVmax analysis and mean SUV corrected for tissue fraction effects were 0.90 and 0.91, respectively. Intensity histograms were different in only 1 of the 13 paired studies. Intraobserver agreement was also excellent (0.80 and 0.85, respectively). Some bias was observed between observers, suggesting that serial studies would benefit from analysis by the same observer.

Conclusion

This study demonstrated that there is excellent short-term reproducibility in pulmonary 18F-FDG uptake in patients with IPF.
Literatur
1.
Zurück zum Zitat Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810–6.PubMedCrossRef Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810–6.PubMedCrossRef
2.
3.
Zurück zum Zitat Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest. 2007;132:637–50.PubMedCrossRef Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest. 2007;132:637–50.PubMedCrossRef
4.
Zurück zum Zitat American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165:277–304. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165:277–304.
5.
Zurück zum Zitat Groves AM, Win T, Haim SB, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol. 2007;8:822–30.PubMedCrossRef Groves AM, Win T, Haim SB, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol. 2007;8:822–30.PubMedCrossRef
6.
Zurück zum Zitat Jeon TY, Lee KS, Yi CA, Chung MP, Kwon OJ, Kim BT, et al. Incremental value of PET/CT Over CT for mediastinal nodal staging of non-small cell lung cancer: comparison between patients with and without idiopathic pulmonary fibrosis. AJR Am J Roentgenol. 2010;195:370–6.PubMedCrossRef Jeon TY, Lee KS, Yi CA, Chung MP, Kwon OJ, Kim BT, et al. Incremental value of PET/CT Over CT for mediastinal nodal staging of non-small cell lung cancer: comparison between patients with and without idiopathic pulmonary fibrosis. AJR Am J Roentgenol. 2010;195:370–6.PubMedCrossRef
7.
Zurück zum Zitat Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG-PET/CT. J Nucl Med. 2009;50:538–45.PubMedCrossRef Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG-PET/CT. J Nucl Med. 2009;50:538–45.PubMedCrossRef
8.
Zurück zum Zitat Umeda Y, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Saito Y, et al. Dual-time-point (18)F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging. 2009;36:1121–30.PubMedCrossRef Umeda Y, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Saito Y, et al. Dual-time-point (18)F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging. 2009;36:1121–30.PubMedCrossRef
9.
Zurück zum Zitat Nusair S, Rubinstein R, Freedman NM, Amir G, Bogot NR, Izhar U, et al. Positron emission tomography in interstitial lung disease. Respirology. 2007;12:843–7.PubMedCrossRef Nusair S, Rubinstein R, Freedman NM, Amir G, Bogot NR, Izhar U, et al. Positron emission tomography in interstitial lung disease. Respirology. 2007;12:843–7.PubMedCrossRef
10.
Zurück zum Zitat Meissner H, Soo-Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration. 2006;73:197–202.PubMed Meissner H, Soo-Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration. 2006;73:197–202.PubMed
11.
Zurück zum Zitat Ambrosini V, Zompatori M, De Luca F, Antonia D, Allegri V, Nanni C, et al. 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med. 2010;51:1950–5.PubMedCrossRef Ambrosini V, Zompatori M, De Luca F, Antonia D, Allegri V, Nanni C, et al. 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med. 2010;51:1950–5.PubMedCrossRef
12.
Zurück zum Zitat Win T, Screaton NJ, Porter J, Endozo R, Wild D, Kayani I, et al. Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[(18)F]fluoro-d-glucose. Mol Imaging. 2011;Sep 28. Epub ahead of print. Win T, Screaton NJ, Porter J, Endozo R, Wild D, Kayani I, et al. Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[(18)F]fluoro-d-glucose. Mol Imaging. 2011;Sep 28. Epub ahead of print.
13.
Zurück zum Zitat Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892–6.PubMedCrossRef Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892–6.PubMedCrossRef
14.
Zurück zum Zitat Lambrou T, Groves AM, Erlandsson K, Screaton N, Endozo R, Win T, et al. The importance of correction for tissue fraction effects in lung PET: preliminary investigation. Eur J Nucl Med Mol Imaging. 2011;38:2238–2246. doi:10.1007/s00259-011-1906-x. Lambrou T, Groves AM, Erlandsson K, Screaton N, Endozo R, Win T, et al. The importance of correction for tissue fraction effects in lung PET: preliminary investigation. Eur J Nucl Med Mol Imaging. 2011;38:2238–2246. doi:10.​1007/​s00259-011-1906-x.
15.
Zurück zum Zitat Studholme C, Hill DLG, Hawkes DJ. An overlap invariant entropy measure of 2D medical image alignment. Pattern Recogn. 1999;32:71–86.CrossRef Studholme C, Hill DLG, Hawkes DJ. An overlap invariant entropy measure of 2D medical image alignment. Pattern Recogn. 1999;32:71–86.CrossRef
16.
Zurück zum Zitat Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Resp Crit Care Med. 1994;150:967–72.PubMed Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Resp Crit Care Med. 1994;150:967–72.PubMed
17.
Zurück zum Zitat Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844–54.PubMedCrossRef Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844–54.PubMedCrossRef
18.
Zurück zum Zitat Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52:690–6.PubMedCrossRef Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52:690–6.PubMedCrossRef
19.
Zurück zum Zitat Chaudhari AJ, Bowen SL, Burkett GW, Packard NJ, Godinez F, Joshi AA, et al. High-resolution (18)F-FDG PET with MRI for monitoring response to treatment in rheumatoid arthritis. Eur J Nucl Med Mol Imaging. 2010;37:1047.PubMedCrossRef Chaudhari AJ, Bowen SL, Burkett GW, Packard NJ, Godinez F, Joshi AA, et al. High-resolution (18)F-FDG PET with MRI for monitoring response to treatment in rheumatoid arthritis. Eur J Nucl Med Mol Imaging. 2010;37:1047.PubMedCrossRef
20.
Zurück zum Zitat Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363–72.PubMedCrossRef Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363–72.PubMedCrossRef
21.
Zurück zum Zitat Ishii H, Nishio M, Takahashi H, Aoyama T, Tanaka M, Toriyama T, et al. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clin Ther. 2010;32:2337–47.PubMedCrossRef Ishii H, Nishio M, Takahashi H, Aoyama T, Tanaka M, Toriyama T, et al. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clin Ther. 2010;32:2337–47.PubMedCrossRef
22.
Zurück zum Zitat Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78.PubMedCrossRef Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78.PubMedCrossRef
23.
Zurück zum Zitat Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 suppl 1:122S–50S.PubMedCrossRef Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 suppl 1:122S–50S.PubMedCrossRef
24.
Zurück zum Zitat Hofman MS, Hicks RJ. Restaging: should we percist without pattern recognition? J Nucl Med. 2010;51:1830–2.PubMedCrossRef Hofman MS, Hicks RJ. Restaging: should we percist without pattern recognition? J Nucl Med. 2010;51:1830–2.PubMedCrossRef
25.
Zurück zum Zitat Chua S, Dickson J, Groves AM. PET imaging for prediction of response to therapy and outcome in oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:1591–4PubMedCrossRef Chua S, Dickson J, Groves AM. PET imaging for prediction of response to therapy and outcome in oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:1591–4PubMedCrossRef
26.
Zurück zum Zitat de Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, et al. Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging. 2009;36:389–95.PubMedCrossRef de Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, et al. Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging. 2009;36:389–95.PubMedCrossRef
27.
Zurück zum Zitat de Langen AJ, Lubberink M, Boellaard R, Spreeuwenberg MD, Smit EF, Hoekstra OS, et al. Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med. 2008;49:1763–8.PubMedCrossRef de Langen AJ, Lubberink M, Boellaard R, Spreeuwenberg MD, Smit EF, Hoekstra OS, et al. Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med. 2008;49:1763–8.PubMedCrossRef
28.
Zurück zum Zitat Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871–8.PubMedCrossRef Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871–8.PubMedCrossRef
29.
Zurück zum Zitat Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, et al. Assessment of inter-observer reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009;50:1760–9.PubMedCrossRef Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, et al. Assessment of inter-observer reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009;50:1760–9.PubMedCrossRef
30.
Zurück zum Zitat Robinson PJ, Kreel L. Pulmonary tissue attenuation with computed tomography: comparison of inspiration and expiration scans. J Comput Assist Tomogr. 1979;3:740–8.PubMed Robinson PJ, Kreel L. Pulmonary tissue attenuation with computed tomography: comparison of inspiration and expiration scans. J Comput Assist Tomogr. 1979;3:740–8.PubMed
31.
Zurück zum Zitat Verschakelen JA, Van-fraeyenhoven L, Laureys G, Demedts M, Baert AL. Differences in CT density between dependent and nondependent portions of the lung: influence of lung volume. AJR Am J Roentgenol. 1993;161:713–7.PubMed Verschakelen JA, Van-fraeyenhoven L, Laureys G, Demedts M, Baert AL. Differences in CT density between dependent and nondependent portions of the lung: influence of lung volume. AJR Am J Roentgenol. 1993;161:713–7.PubMed
32.
Zurück zum Zitat Nobuta M, Miyauchi M, Mimura K, Matsuoka A, Sugita M, Kitada O. Influence of body positions on phase IV in a single nitrogen breath method. Rinsho Byori. 1981;29:1062–6.PubMed Nobuta M, Miyauchi M, Mimura K, Matsuoka A, Sugita M, Kitada O. Influence of body positions on phase IV in a single nitrogen breath method. Rinsho Byori. 1981;29:1062–6.PubMed
33.
Zurück zum Zitat Inoue K, Okada K, Taki Y, Goto R, Kinomura S, Fukuda H. 18FDG uptake associated with CT density on PET/CT in lungs with and without chronic interstitial lung diseases. Ann Nucl Med. 2009;23:277–81.PubMedCrossRef Inoue K, Okada K, Taki Y, Goto R, Kinomura S, Fukuda H. 18FDG uptake associated with CT density on PET/CT in lungs with and without chronic interstitial lung diseases. Ann Nucl Med. 2009;23:277–81.PubMedCrossRef
34.
Zurück zum Zitat McQuaid SJ, Hutton BF. Sources of attenuation-correction arefacts in cardiac PET/CT and SPECT/CT. Eur J Nucl Med Mol Imaging. 2008;35:1117–23.PubMedCrossRef McQuaid SJ, Hutton BF. Sources of attenuation-correction arefacts in cardiac PET/CT and SPECT/CT. Eur J Nucl Med Mol Imaging. 2008;35:1117–23.PubMedCrossRef
35.
Zurück zum Zitat Dawood M, Lang N, Jiang X, Schafers KP. Lung motion correction on respiratory gated 3-D PET/CT images. IEEE Trans Med Imaging. 2006;25:476–85.PubMedCrossRef Dawood M, Lang N, Jiang X, Schafers KP. Lung motion correction on respiratory gated 3-D PET/CT images. IEEE Trans Med Imaging. 2006;25:476–85.PubMedCrossRef
Metadaten
Titel
18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials
verfasst von
Thida Win
Tryphon Lambrou
Brian F. Hutton
Irfan Kayani
Nicholas J. Screaton
Joanna C. Porter
Toby M. Maher
Raymondo Endozo
Robert I. Shortman
Pauline Lukey
Ashley M. Groves
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1986-7

Weitere Artikel der Ausgabe 3/2012

European Journal of Nuclear Medicine and Molecular Imaging 3/2012 Zur Ausgabe